Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -6334.04% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSCYNEXIS INC's latest supported as-filed period reports revenue of $235,000, 82.8% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -6334.04% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -82.77% · CORE
Level · gp.fundamentals.operating_margin
Raw value -3308.51% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 1655.74% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 241.70% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 4.8%; Operating cash flow decreased 98.6%.
2 evidence-backed componentsShares outstanding changed -76.3% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes. This reverses 8 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
SCYX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001178253-26-000031SEC ↗10-QAug 10, 2026Period Jun 30, 20260001178253-26-000027SEC ↗4Jun 30, 2026Period Jun 26, 20260001797160-26-000002SEC ↗4Jun 30, 2026Period Jun 26, 20260001296998-26-000002SEC ↗4Jun 30, 2026Period Jun 26, 20260001219866-26-000002SEC ↗4Jun 30, 2026Period Jun 26, 20260001237401-26-000002SEC ↗4Jun 30, 2026Period Jun 26, 20260001286338-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed -98.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating margin changed -260756 basis points from the comparable as-filed period.
Research & development changed -45.5% from the comparable as-filed period.
Revenue changed -82.8% from the comparable as-filed period.
Operating income changed +18.7% from the comparable as-filed period.
Stock-based compensation changed -30.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001178253-26-000021